secwatch.observer — SEC 8-K summary
======================================

Issuer:     Virpax Pharmaceuticals, Inc. (—)
CIK:        0001708331
Form:       8-K
Filed at:   2025-04-03T23:59:59+00:00
Accession:  0001731122-25-000521
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 3.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq delisting Virpax; directors and CFO resign effective immediately
-----------------------------------------------------------------------

- Nasdaq Hearings Panel determined to delist Virpax due to failure to meet minimum stockholders' equity under Rule 5550(b)(1).
- Trading suspended at open on April 4, 2025; Company not appealing.
- Three directors (Esha Randhawa, Charn Deol, Judy Su) resigned April 2, 2025.
- CFO Usama Chaudhry resigned same day, effective immediately; no disagreements cited.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708331/000173112225000521/0001731122-25-000521-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708331/000173112225000521/e6489_8k.htm
  HTML page:      https://secwatch.observer/filing/0001731122-25-000521

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer